Abstract

Objective(s): Saffron, the dehydrated stigma of the Crocus sativus L. flower, has been reputed as an effective anticancer and chemopreventive agent in cancer therapy. This study aimed to design PEGylated nanoliposomes containing crude extract of saffron for the treatment of cancer.Materials and Methods: Various PEGylated nanoliposomes containing 25 mg/ml aqueous extract of saffron were prepared using the thin lipid film method. The characterization of liposomes was indicated by their size, in vitro cytotoxicity, and in vivo therapeutic efficacy against C26 tumor-bearing mice. Results: By increasing cholesterol levels, the IC50 values of the formulations increased. Liposome characterization illustrated the properties of formulation of choice, as follows: Z-average size: 73.7 ± 1.3 nm; PDI: 0.103 ± 0.035; zeta potential: -20.8 mV ± 3.7; % encapsulation: 91 ± 0.059, % release after 168 hours in 30% FBS: 16.26 ± 0.01.Conclusion: Treating tumor-bearing mice with the selected saffron liposomes indicated that, for the first time, the i.v. injection of nano-liposomal saffron at a dose of 300 mg/kg significantly increased the anti-tumor property compared to the negative control group, while no significant difference was observed compared with aqueous extract of saffron. Hence, to achieve an optimal formulation for human use, the formulation merits further study.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.